A DAP12-mediated Pathway Regulates Expression of CC Chemokine Receptor 7 and Maturation of Human Dendritic Cells

Axel Bouchon, Cristina Hernández-Munain, Marina Cella, and Marco Colonna

Basel Institute for Immunology, CH-4005 Basel, Switzerland

Abstract

Gene targeting of the adaptor molecule DAP12 in mice caused abnormal distribution and impaired antigen presentation capacity of dendritic cells (DCs). However, the DAP12-associated receptors expressed on DCs and their functions have not been identified yet. Here we show that the triggering receptor expressed on myeloid cells-2 (TREM-2) is a cell surface receptor on human monocyte-derived DCs, which is associated with DAP12. TREM-2/DAP12 promotes upregulation of CC chemokine receptor 7, partial DC maturation, and DC survival through activation of protein tyrosine kinases and extracellular signal–regulated kinase. In contrast to Toll-like receptor-mediated signaling, TREM2/DAP12 stimulation is independent of nuclear factor-κB and p38 stress-activated protein kinase. This novel DC activation pathway may regulate DC homeostasis and amplify DC responses to pathogens, explaining the phenotype observed in DAP12-deficient mice.

Key words: TREM • activation • human • survival • migration

Introduction

Dendritic cells (DCs)* are a distinct population of bone marrow–derived leukocytes that initiate primary and secondary immune responses (1). DCs migrate from the blood to peripheral tissues, where they reside in an immature state, awaiting antigen encounter. Upon antigen capture, DCs process them into peptides, which are loaded onto MHC molecules for presentation to T cells. As a result of pathogen invasion, inflammation, and tissue damage, DCs receive additional activating signals, which induce a profound change in DC phenotype and functions, known as maturation (1–3). Mature DCs express the chemokine receptor CCR7, which interacts with the chemokines CCL19 (also known as EBI-1 ligand chemokine [ELC], or macrophage inflammatory protein 3 β [MIP-3β]) and CCL21 (also known as secondary lymphoid tissue chemokine [SLC], or 6-C–Kine) (4–9). These chemokines are crucial for guiding DCs from peripheral tissues to draining lymph nodes, as demonstrated in mice with natural or targeted genetic deletions of CCL19, CCL21, or CCR7 (10–14). In addition, mature DCs express high levels of stable MHC-peptide complexes on the cell surface, upregulate costimulatory and adhesion molecules, and downregulate antigen-capturing molecules. Thus, mature DCs can efficiently present antigens and stimulate virgin-T cells located in the T cell–rich areas of lymph nodes (1, 15). Here, DCs receive further activating signals from cognate Th cells, which express CD40 ligand (CD40L) (16), OX40 (17, 18), and TNF-related activation-induced cytokine (TRANCE) (19–22). These stimuli trigger IL-12 secretion by antigen presenting DCs thus promoting Th1 type T cell responses (20, 23–27).

Activating signals induce DC maturation through several distinct signaling pathways. LPS, other bacterial and viral components, as well as products released by damaged tissues, activate DCs through Toll-like receptors (TLRs) (28, 29). TLRs trigger downstream signaling pathways, which activate the nuclear factor (NF)-κB. NF-κB promotes the transcription of a variety of genes mediating maturation (30–33). In addition, TLRs activate mitogen-activated pro-
tein kinases (MAPks), such as the stress-activated protein kinase p38 (p38/SAPK) and the extracellular signal-regulated kinase (ERK), which concur to DC activation (28, 29). Inflammatory cytokines, such as IL-1, IL-18, and TNF-\(\alpha\), and T cell surface molecules, such as CD40L, OX40, and TRANCE, bind specific receptors that activate NF-\(\kappa\)B as well (1, 20, 34–37). A second pathway of DC maturation is initiated by the receptors for the Fc portion of IgG (FcRs), which bind antibody-opsonized pathogens (38). FcRs lack intracellular signaling motifs, but display a charged residue in the transmembrane domain, which mediates association with the \(\gamma\) chain of FcR (FcR\(\gamma\)) (39). FcR\(\gamma\) contains a cytoplasmic immunoreceptor tyrosine-based activation motif (ITAM), which recruits protein tyrosine kinases (PTKs) of the src and syk families. PTKs trigger protein tyrosine phosphorylation, \(Ca^{2+}\) mobilization, and phosphorylation of several MAPks (40, 41). While FcR\(\gamma\) is essential for FcR-mediated DC maturation (42), the role of downstream PTKs and MAPks is yet unknown.

Recent observations suggest that DC activation is controlled by yet another signaling pathway, which involves the adaptor molecule DAP12 (also called KARAP). DAP12 is associated with several NK and myeloid cells activating receptors (43–54). Like FcR\(\gamma\), DAP12 contains a cytoplasmic ITAM, recruits the PTKs ZAP70 and p72/syk, and promotes activation of ERK (44, 45, 55, 56). Knock-in mice bearing a nonfunctional mutation within the ITAM of DAP12 showed a dramatic accumulation of DCs in mucocutaneous epithelia and were resistant to hapten-specific contact sensitivity (57). In addition, DAP12-deficient mice were resistant to experimental autoimmune encephalomyelitis (EAE) induced by immunization with myelin oligodendrocyte glycoprotein peptide (58). These phenotypes suggested a role of DAP12 in regulating migration and antigen presentation capacity of DCs. Three DAP12-associated receptors have been identified in myeloid cells. One of these, myeloid DAP12-associated lectin-1 (MDL-1), is a member of the C-type lectin superfamily (50). The others, signal-regulatory protein \(\beta\) (SIRP-\(\beta\)) and triggering receptor expressed on myeloid cells-1 (TREM-1), belong to the Ig superfamily (53, 59). TREM-1 is preferentially expressed on neutrophils and a subset of blood monocytes (53). SIRP-\(\beta\) and MDL-1 are mainly expressed on blood monocytes and macrophages (50, 56). When monocytes are differentiated toward DCs by culturing them in vitro in the presence of GM-CSF and IL-4, expression of MDL-1, SIRP-\(\beta\), and TREM-1 is completely downregulated (50, 53, 56).

Recently, we have cloned a cell surface receptor distantly related to TREM-1 called TREM-2. TREM-2 is a member of the Ig superfamily characterized by a single V-type extracellular domain, a transmembrane region with a charged residue of lysine and a short cytoplasmic tail with no signaling motifs (53). Here we found that TREM-2 is associated with DAP12 and, in contrast to TREM-1, SIRP-\(\beta\), and MDL-1, is not expressed on monocytes, but it is strongly upregulated on human DCs derived in vitro from monocytes. This observation provided the opportunity to investigate the role of TREM2/DAP12-mediated signaling pathways in DC migration and maturation.

**Materials and Methods**

**Production of TREM-2 Human IgM Fusion Protein.** Soluble TREM-2 was produced as a chimeric protein consisting of TREM-2 extracellular domain and human IgM constant regions (TREM-2 human IgM [TREM-2-HuIgM]), as previously described (61). TREM-2 extracellular domain was amplified from the cloned full length cDNA by polymerase chain reaction using the following oligonucleotides: 5’-ACTCTGCTTCTGGCCCTTGGCTGGGG, 3’-tagagTCTGACATCTAACC GGTTGGAAGGGATTTCCTCCCTCAA. Purification of TREM-2-HuIgM from culture supernatants was performed by affinity chromatography on Sepharose-coupled mouse anti-human IgM mAb (Sigma-Aldrich) according to manufacturer’s protocols.

**Transfections.** 293 cells were transiently transfected with a cDNA encoding human TREM-2 as a FLAG peptide NH-ter-

**Production and Modifications of Anti-TREM-2 and Control mAbs.** 6-wk-old BALB/c mice (Iffa-Credo) were immunized with purified TREM-2-HuIgM. Spleen cells were fused with the SP2/0 myeloma cells and hybridoma supernatants were screened by ELISA using TREM-2-HuIgM as capturing protein and human-adsorbed horseradish peroxidase (HRP)-labeled goat anti-mouse IgG (BD PharMingen) as detecting Ab. ELISA-positive hybridoma supernatants were then tested by flow cytometry for staining 293 cells expressing FLAG-tagged TREM-2. mAb 29E3 (anti-TREM-2, IgG1, \(\kappa\)), mAb 21C7 (control IgG1, \(\kappa\), anti-TREM-1) (53), and mAb 1B7.11 (control IgG1, \(\kappa\), anti-2,4,6 TNP; American Type Culture Collecti)

**Antibodies and Flow Cytometry.** Before staining, all cells were incubated with PBS-20% human serum for 1 h on ice to block Fc receptors (FcR). Monocyes cultured in M-CSF or GM-CSF and IL-4 were stained with either mAb 29E3, mAb 21C7, or F(ab’2) fragments were biotinylated allowing for crosslinking by ExtrAvidine (Sigma-Aldrich) or flow cytometry by Streptavidin-allophycocyanin (APC) or -PE (BD PharMingen). Alternatively, F(ab’2) fragments were crosslinked using a goat anti-mouse IgG F(ab’2) specific antibody (The Jackson Laboratory).

**Cells.** PBMCs were purified from human blood by gradient density centrifugation on lymphocyte separation medium (LSM; ICN Biomedicals/Cappel). CD14+ monocytes were purified from PBMCs by magnetic cell sorting (MACS) using CD14 MicroBeads (Miltenyi Biotec). Monocyte-derived DCs were prepared from purified monocytes as described previously (62, 63).

**Antibodies and Flow Cytometry.** Before staining, all cells were preincubated with PBS-20% human serum for 1 h on ice to block Fc receptors (FcR). Monocytes cultured in M-CSF or GM-CSF and IL-4 were stained with either mAb 29E3, mAb 21C7, or mAb 1B7.11, followed by human-adsorbed PE-conjugated goat anti-mouse IgG (Southern Biotechnology Associates, Inc.). In three-color stainings, immature DCs cultured with LPS (100 ng/ml), TNF-\(\alpha\) (10 ng/ml), or CD40L-transfected J558L cells (64) were incubated with Cy5-labeled mAbs 29E3 and FITC-conju-
gated anti-CD83 mAb (Immunotech). Cells were analyzed on a FACSCalibur™ cytometer using CELLQuest™ software (Becton Dickinson). Dead cells were excluded by gating on PI-negative cells.

Stimulation of DCs by LPS, F(ab′)2, Anti–TREM-2 mAb, or Human IgG in the Presence or Absence of Inhibitors. Human IgG, F(ab′)2, 29E3 (anti–TREM-2 mAb), or control F(ab′)2 (21C7 anti–TREM-1 mAb) were coated for 6 h at 37°C on 96-well flat-bottom plates with a final concentration of 20 μg/ml in PBS. LPS was used at a final concentration of 1 μg/ml. Immature DCs were plated at a concentration of 5 × 10⁴ cells/well and simultaneous contact to the plate was induced by short centrifugation (400 g, 1 min, 25°C). Supernatants and cells were collected after 6, 12, 24, 36, and 48 h and tested by ELISA or flow cytometry. In blocking experiments, inhibitors (PD98059 [20 μM], LY294002 [10 μM], SB203580 [2 μM], PP2 [1 μM]; all from Calbiochem), and TPCK (20 μM; Sigma–Aldrich) were added 60 min before stimulation.

Measurement of Cytokines, Chemokines, and Cell Surface Activation Markers. To measure stimulation-dependent changes in the expression of cell surface markers and cytokine secretion, monocye-derived DCs were stimulated as described above for 6, 12, 24, 48, and 72 h. Supernatants were collected and tested for production of IL-6, IL-8, IL-10, TNF-α, and MCP-1 by ELISA (BD PharMingen). Cells were harvested and stained with anti–TREM-2, -MHC class I, -MHC class II, -CD1a, -CD11a, -CD11b, -CD11c, -CD29, -CD32, -CD35, -CD38-, -CD40-, -CD41, -CD54, -CD61, -CD64, -CD80, -CD83, -CD86, -CD89, -CD103, -CD11b, -CD11c, -CCR5, -CCR6, -CXC4, -CXC6, or -Mannose receptor conjugated with Cy5-, PE-, or FITC (all from Immunotech and BD PharMingen). Anti–CCR7 mAb (BD PharMingen) was followed by F(ab′)2, PE-labeled goat anti–mouse IgM Ab (Southern Biotechnology Associates, Inc.). Stained cells were analyzed by flow cytometry.

Measurement of Cytosolic Ca²⁺. Monocyte-derived DCs were loaded with Indo-1 AM (Sigma–Aldrich) for 30 min at 37°C, washed three times, and resuspended in RPMI/10 mM HEPES/5% FCS. Cytosolic Ca²⁺ levels were monitored in individual cells by measuring 405/525 spectral emission ratio of loaded Indo-1 dye by flow cytometry. After a baseline was acquired for at least 30 s, 29E3, 21C7, F(ab′)2 29E3, F(ab′)2 21C7, F(ab′)2 29E3, or F(ab′)2 21C7 were added to a final concentration of 1 μg/ml and analysis was continued up to 512 s. All antibodies and antibody fragments were biotinylated. In some experiments, ExtraAvidine (Sigma–Aldrich) was added as crosslinker together with the biotinylated primary antibodies or Ab fragments.

Determination of ERK, JNK, and p38/SAPK Activation. Monocyte-derived DCs (10⁶ cells per time point) were stimulated as described above. After 0 (unstimulated control), 1, 2, 5, 10, and 20 min cells were harvested and chilled on ice. Cells were spun down and lysed in reducing sample buffer. Specific induction of tyrosine phosphorylation and phosphorylation of ERK, p38/SAPK, and JNK was determined by reducing Western blot analysis using anti–phospho-ERK, anti–ERK, anti–phospho- p38/SAPK, anti–p38/SAPK, anti–phospho-JNK, and anti–JNK antibodies (all from New England Biolabs, Inc.).

Surface Biotinylation and Pervanadate Treatment. Monocyte-derived DCs were washed three times in PBS followed by incubation with sulfo-NHS-biotin according to the manufacturer’s protocol (Pierce Chemical Co.). For pervanadate treatment, cells were incubated with 200 μM pervanadate and 200 μM H₂O₂ at 37°C for 5 min. Biotinylation or pervanadate stimulation was stopped by washing the cells three times in PBS/10% FCS/200 μM pervanadate and one time with ice cold PBS/200 μM pervanadate, respectively.

Immunoprecipitations. Surface-biotinylated cells were lysed in 1% digitonin, 100 mM Tris-HCl, pH 7.4, 150 mM NaCl, protease inhibitors (Complete; Roche Molecular Biochemicals). After overnight preclearing with normal mouse serum coupled to protein G Sepharose 4B (Amersham Pharmacia Biotech), lysates were subjected to immunoprecipitation with 5 μg/ml of 29E3, 21C7, or 1B7.11 at 4°C. Immunocomplexes were precipitated by addition of protein-G-Sepharose 4B for 3 h at 4°C. Precipitates were washed four times with lysis buffer, followed by a final wash with 0.5% digitonin, 100 mM Tris-HCl, pH 7.4, 150 mM NaCl. After separation by SDS-PAGE, precipitates were analyzed by Western blot with HRP-conjugated streptavidin. In deglycosylation experiments the precipitates were incubated for 18 h with or without N-Glycanase F (Roche) according to the manufacturer’s protocol. Pervanadate-treated cells were subjected to immunoprecipitation as described above. Immunoprecipitates were analyzed by Western blot with antiphosphotyrosine PY20/HRP (Transduction Laboratories) or anti-DAP12 rabbit antiserum followed by human/mouse-adsorbed anti–rabbit IgG–HRP (Southern Biotechnology Associates, Inc.).

Chemotaxis Assay. Monocyte-derived human DCs (10⁷) were treated for 24 h with F(ab′)2 21C7, F(ab′)2 29E3 coated on plastic (20 μg/ml), or LPS (1 μg/ml). Cells (5 × 10⁴ in 100 μl IMDM/0.5% BSA) were incubated for 1 h at 37°C. Cells were subsequently loaded into collagen-coated Transwells (Costar; 3-μm pore filters), which were placed onto 24-well plates containing 450 μl medium supplement with 100 ng/ml CCL19 (ELC/MIP-3β) or CCL20 (6-C-Kine/SLC) (both from PeproTech). After an incubation period of 4 h at 37°C, cells that had migrated to the lower chamber were collected and counted on a cytofluorometer (FACSCalibur™, constant time measurement; Becton Dickinson). In blocking experiments cells were preincubated with anti–CCR7 mAb (10 μg/ml) and added to the Transwell.

Detection of Apoptosis. Determination of DNA fragmentation was performed as described previously (65). Inhibitors of kinases or serine proteases (PD98059 [20 μM], LY294002 [10 μM], TPCK [20 μM]) were added 60 min before stimulation. Inhibitors had no effect on cell viability or the rate of constitutive apoptotic symptoms at the indicated concentrations.

Nuclear Extracts and Electrophoretic Mobility Shift Assays. Nuclear extracts were prepared according to the method of Schreiber et al. (66) with some modifications. Stimulation of monocyte-derived human DCs (10⁷) with control or anti–TREM-2 antibodies or with LPS was performed for 0.5 or 4 h at 37°C as described above. Cells were washed in PBS, resuspended in 10 ml of ice-cold buffer A (10 mM Tris–HCl, pH 7.9, 60 mM KCl, 1 mM EDTA, 0.75 mM spermidine, 0.15 mM spermine, 1 mM DTT, 0.5 mM PMSF, 1 μg/ml aprotinin, 1 μg/ml leupeptin, and 1 μg/ml pepstatin), and incubated for 15 min on ice. Nonidet P-40 was added from a 10% stock solution to a final concentration of 0.6%, and samples were vortexed for 10 s. After incubation for 3 min on ice, samples were centrifuged at 3,000 rpm for 10 min at 4°C. Nuclei were washed in 10 ml of ice-cold buffer A and resuspended in 30 ml of ice-cold buffer C (20 mM Tris–HCl, pH 8, 0.4 M NaCl, 1.5 mM MgCl₂, 1 mM EDTA, 1 mM DTT, 0.5 mM PMSF, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml pepstatin, and 25% glycerol). Nuclei were incubated for 30 min at 4°C, and nuclear extracts were separated from debris by centrifugation at 15,000 g for 15 min at 4°C. Protein concentrations were determined by Bradford assay using Bio–Rad protein assay (Bio-Rad Laboratories). NF-κB consensus and mutant binding sites
were 5'-AGTTGAGGGGACTTTCCCAGGC-3' and 5'-AGTTGAGGGGACTTTCCCAGGC-3', respectively. Annealed binding sites were radiolabeled using polynucleotide T4 kinase and γ[^32P]-ATP. Radiolabeled oligonucleotides were purified by electrophoresis through an 8% polyacrylamide gel containing 22.5 mM Tris-borate and 0.5 mM EDTA, overnight elution from gel slices at 37°C, concentration using Elutip-d columns (Schleicher & Schuell), and ethanol precipitation. Electrophoretic mobility assays (EMSA) were performed as described previously (67) with some modifications. Nuclear extracts (2 μg) were incubated with 1 μg of poly(dI-dC) carrier and 1 μg of BSA in a 25 μl reaction mix containing 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM DTT, 1 mM EDTA, and 5% glycerol for 10 min at 4°C in the presence or absence of 25-fold excess of unlabeled oligonucleotide competitors. Labeled binding-site probes (15 fmols, ~5 × 10⁴ cpm) were then added for an additional 20 min of incubation at 4°C. Samples were electrophoresed through a 4% polyacrylamide gel containing 22.5 mM Tris-borate and 0.5 mM EDTA at 4°C.

**Results**

**Human Immature Monocyte-derived DCs Express TREM-2, a ~40 kD Glycoprotein which Is Associated with DAP12.** In initial studies, TREM-2 transcript was selectively detected in monocyte-derived DCs by reverse transcriptase (RT)-PCR (data not shown). To precisely investigate the cellular distribution of TREM-2 as well as its biochemical characteristics and functions, we produced an anti–TREM-2 mAb (29E3). This antibody stained TREM-2–transfected 293 cells specifically, compared with control transfectants (Fig. 1 A). In agreement with RT-PCR data, TREM-2 was highly expressed on DCs derived from peripheral blood monocytes upon in vitro culture with GM-CSF and IL-4 (Fig. 1 B). DC maturation induced by LPS, TNFα, CD40L-expressing cells (Fig. 1 C), IL-1β, CpG oligonucleotides, or aggregated IgG (data not shown) led to complete downregulation of TREM-2. TREM-2 was undetectable on macrophages obtained by culturing monocytes up to 14 d with M-CSF (Fig. 1 B) and on primary DCs of peripheral blood (data not shown). Thus, TREM-2 is preferentially expressed on immature monocyte-derived DCs.

Immunoprecipitation of TREM-2 from surface-biotinylated monocyte-derived DCs revealed that TREM-2 is a glycoprotein of ~40 kD, that is reduced to 26 kD after N-deglycosylation (Fig. 2 A). This result is in agreement with the predicted molecular mass of TREM-2 (53). As TREM-2 lacks known signaling motifs in the cytoplasmic domain and displays a charged residue of lysine in the transmembrane domain (53), it was likely to be associated with a separate adaptor molecule to transduce signals. Adaptor molecules, such as DAPI2, DAP10, and FcγR are tyrosine phosphorylated upon cell treatment with the phosphatase inhibitor pervanadate (44, 68, 69). Indeed, anti-phosphoty-

![Image 1](attachment:image.png)
Rosine blotting of TREM-2 immunoprecipitates from pervanadate-stimulated monocyte-derived DCs revealed a phosphorylated protein of ~14 and ~28 kD under reducing and nonreducing conditions, respectively (Fig. 2 B). This pattern was consistent with the association of TREM-2 with a tyrosine-phosphorylated protein that forms a disulfide-linked homodimer. Immunoblotting of TREM-2 immunoprecipitates with anti-DAP12, -DAP10, and -Fcγ antisera demonstrated that TREM-2, like TREM-1, associates only with DAP12 (Fig. 2 C, and data not shown). Thus, TREM-2 is capable of stimulating DAP12-linked signaling pathways in DCs.

**TREM-2 Induces ERK Activation and Survival of DCs.** To see whether the TREM-2/DAP12 complex transduces activating signals in DCs as other DAP12-associated receptors do in NK cells and neutrophils (43–45, 47–54, 56, 70), we stimulated TREM-2 with 29E3 mAb or with its F(ab')2 fragment. In both cases, ligation of TREM-2 elicited a rapid rise in intracellular Ca\(^{2+}\) concentration of DCs (Fig. 3 B). However, monovalent engagement of TREM-2 using F(ab')2 29E3 did not induce calcium mobilization, indicating that TREM-2–mediated activation needs at least two or more receptors crosslinked (data not shown). Crosslinking of TREM-2 with F(ab')2 29E3 stimulated tyrosine phosphorylation of several proteins with approximate molecular masses of ~110, ~90, ~60–70, and ~30–40 kD (Fig. 3 C). The observed ~40 kD tyrosine phosphorylated proteins corresponded to the ERK1/2, as demonstrated by antiphospho-ERK1/2 immunoblotting (Fig. 3 D). It was previously shown that survival of LPS-stimulated DCs is dependent on ERK (71) and phosphatidylinositol 3-kinase (PI-3K) (72), while maturation is mainly mediated through NF-κB. Therefore, we tested whether stimulation of TREM-2 leads to prolonged survival of DCs kept in culture in the absence of GM-CSF or IL-4. As shown in Fig. 3 E, crosslinking of TREM-2 with F(ab')2 29E3 prolonged DC survival for almost 8 d. Treatment of TREM-2–stimulated DCs with the ERK inhibitor PD98059 blocked this survival effect. Inhibitors of PI-3K, IκB-phosphorylation, or IκB-degradation had no effect (Fig. 3 F, and data not shown). These observations indicate that TREM-2 induces survival of DCs through activation of the ERK pathway.

**TREM-2 Triggers Rapid Upregulation of CCR7 and Increased Expression of MHC Class II, CD86, and CD40.** To examine whether TREM-2 can trigger migration of DCs and/or their maturation into efficient antigen-presenting cells, immature DCs were stimulated with F(ab')2 29E3 mAb coated on plastic surface. These cells were tested for the expression of cell surface molecules involved in migration, antigen presentation, costimulation, and adhesion, as well as for the production of cytokines. Upon TREM-2 ligation, CCR7 surface expression was rapidly increased (Fig. 4 A). CCR7 was functionally competent, as TREM-2–stimulated DCs showed a specific chemoattractic response towards the CCL19 and CCL21, which could be inhibited by anti-CCR7 mAb (Fig. 4 B). The amplitude and kinetics of CCR7 upregulation induced via TREM-2 were different compared with those induced by
LPS stimulation (Fig. 4 A). While expression of CCR7 was detectable by 6 h after TREM-2 stimulation, LPS-induced upregulation of CCR7 was weaker and occurred only after 24 h of cell stimulation. Regardless of CCR7 surface levels, however, LPS-stimulated DCs displayed a stronger chemotactic response toward CCL19 and CCL21 than TREM-2–stimulated DCs. Therefore, DC mobility and chemotaxis to CCL19 and CCL21 is not solely related to CCR7 expression levels. Indeed, it has been shown that other receptors, such as the multidrug resistance-associated protein 1, can contribute to optimal mobilization of DCs from skin to secondary lymphoid organs (73).
Table I. **TREM-2–dependent Regulation of Cell Surface Activation Markers**

|          | F(\(\text{ab}\)^\(_2\))\_1 anti–TREM-1 | F(\(\text{ab}\)^\(_2\))\_2 anti–TREM-2 | LPS   |
|----------|-----------------------------------------|---------------------------------------|-------|
| TREM-2   | 112.23                                  | 3.45                                  | 7.1   |
| MHC class I | 67.8                                   | 65.3                                  | 107.1 |
| MHC class II | 119.12                                 | 278.65                                | 454.67|
| CD40     | 171.35                                  | 598.6                                 | 635.89|
| CD80     | 32.1                                    | 39.4                                  | 104.6 |
| CD86/B7.2 | 14.04                                   | 387.91                                | 683.56|
| CCR5     | 12.95                                   | 13.56                                 | 3.12  |
| CCR6     | 3.68                                    | 3.45                                  | 4.01  |
| CCR7     | 6.82                                    | 21.98                                 | 12.45 |
| CXCR4    | 5.13                                    | 4.56                                  | 17.8  |
| CD11a    | 10.92                                   | 6.78                                  | 13.72 |
| CD11b    | 53.9                                   | 65.7                                  | 23.1  |
| CD11c    | 91.1                                   | 65.7                                  | 123.5 |
| CD29     | 38.22                                   | 37.56                                 | 37.5  |
| CD41     | 4.54                                    | 4.67                                  | 4.39  |
| CD54/ICAM-1 | 56.87                                 | 54.78                                 | 271.45|
| CD61     | 4.95                                    | 5.03                                  | 4.21  |
| CD103    | 3.63                                    | 3.96                                  | 3.26  |
| Mannose-R | 81.8                                    | 82.9                                  | 30.9  |
| CD64/FcyR I | 9.8                                   | 10.1                                  | 2.3   |
| CD32/FcyR II | 17.21                                 | 16.78                                 | 2.34  |
| CD89/FcαR | 4.54                                    | 4.75                                  | 4.96  |
| CD35/CR1 | 3.94                                    | 4.23                                  | 3.67  |
| M-CSF-R  | 14.6                                    | 4.23                                  | 5.21  |
| GM-CSF-R | 15.6                                    | 13.7                                  | 13.5  |
| CD38     | 2.5                                     | 2.2                                   | 43.5  |
| CD83     | 3.34                                    | 3.23                                  | 26.7  |
| CD1a     | 106.76                                  | 134.9                                 | 87.54 |

DCs were cultured for 48 h in plates coated with control F(\(\text{ab}\)^\(_2\))\_2, F(\(\text{ab}\)^\(_2\))\_1 anti–TREM-2 mAb, or LPS as indicated in Fig. 6. Cells were subsequently analyzed by flow cytometry for the indicated cell surface molecules. Numerical values indicate specific mean fluorescence intensity after subtraction of the fluorescence detected with an isotype-matched control. The data shown are representative of four independent experiments.

Ligation of TREM-2 also induced increased cell surface expression of several molecules involved in T cell stimulation, such as MHC class II, CD40, and CD86 (Table I). In contrast to LPS-activated DCs, CD83 and intracellular adhesion molecule (ICAM)-1 were not upregulated. Furthermore, antigen-capturing molecules, such as CD32, CD64, and the mannose receptor, were not downregulated (Table I). DCs activated through TREM-2 did not secrete either IL-12, or other cytokines (Table II). Thus, TREM-2 mediates a unique pattern of DC activation, characterized by upregulation of CCR7, expression of some T cell stimulatory molecules, and lack of cytokine secretion.

Table II. **Lack of Cytokine and Chemokine Secretion upon TREM-2 Engagement**

|         | F(\(\text{ab}\)^\(_2\))\_2 anti–TREM-1 | F(\(\text{ab}\)^\(_2\))\_2 anti–TREM-2 | LPS   |
|---------|----------------------------------------|--------------------------------------|-------|
| IL-1α   | N.D.                                   | N.D.                                 | 0.135 ± 0.026 |
| IL-1β   | 0.027 ± 0.012                          | N.D.                                 | 0.162 ± 0.09 |
| TNF-α   | 0.042 ± 0.005                          | N.D.                                 | 4.015 ± 0.078 |
| IL-18   | N.D.                                   | N.D.                                 | 2.56 ± 1.31 |
| IL-6    | N.D.                                   | N.D.                                 | 16.7 ± 5.43 |
| IL-10   | N.D.                                   | N.D.                                 | 2.03 ± 0.45 |
| TGF-β1  | N.D.                                   | N.D.                                 | N.D.   |
| IL-12p40| N.D.                                   | N.D.                                 | 3.48 ± 1.25 |
| IL-12p70| N.D.                                   | N.D.                                 | 1.45 ± 0.09 |
| IL-13   | N.D.                                   | N.D.                                 | N.D.   |
| IL-15   | N.D.                                   | N.D.                                 | N.D.   |
| MCP-1   | 2.018 ± 0.875                          | 0.449 ± 0.067                        | 98.18 ± 35.86 |
| IL-8    | 1.23 ± 0.451                           | 0.023 ± 0.01                        | 124.76 ± 23.91 |

Cells were stimulated as described in Fig. 6. Cell supernatants were analyzed by ELISA for secretion of the indicated cytokines and chemokines. Data are representative for three independent experiments. Values are shown in pg/ml. N.D., not detectable.

more, antigen-capturing molecules, such as CD32, CD64, CD89, and the mannose receptor, were not downregulated (Table I). DCs activated through TREM-2 did not secrete either IL-12, or other cytokines (Table II). Thus, TREM-2 mediates a unique pattern of DC activation, characterized by upregulation of CCR7, expression of some T cell stimulatory molecules, and lack of cytokine secretion.

**TREM-2 Does Not Activate IκBα/NF-κB or p38/SAPK Signaling Pathways.** LPS-induced maturation of DCs requires the activity of NF-κB transcription factor (74–76). Prior to activation, NF-κB is retained in the cytoplasm through binding to the inhibitory IκB protein. Stimulation of cells with LPS leads to IκB kinase (IKK)-mediated phosphorylation of IκB. This is followed by rapid ubiquitination and proteolytic degradation of IκB, allowing nuclear translocation of NF-κB and binding to κB-promoter elements (30–33, 77). To study whether TREM-2 activates the IκBα/NF-κB pathway, we stimulated DCs through TREM-2 and analyzed the phosphorylation of IκBα by Western blot analysis. In addition, we assessed the nuclear translocation of NF-κB by searching for NF-κB–containing complexes in EMSAs. In striking contrast to LPS (72), antibody-mediated ligation of TREM-2 did not lead to phosphorylation and degradation of IκBα (Fig. 5 A) or nuclear translocation of NF-κB (Fig. 5 B). It was previously shown that LPS-induced maturation of DCs is also mediated by activation of p38/SAPK (72, 78). To see whether TREM-2 activates p38/SAPK, we crosslinked TREM-2 on DCs with F(\(\text{ab}\)^\(_2\))\_2, 29E3 and analyzed tyrosine phosphorylation of p38/SAPK by Western blot analysis. In contrast to LPS, TREM-2 did not induce p38/SAPK tyrosine phosphorylation (Fig. 5 C).
Thus, the TREM-2–induced activation pathway is NF-κB- and p38/SAPK independent.

**TREM-2 Induces DC Maturation through an ERK- and PTK-dependent, NF-κB, and p38/SAPK-independent Pathway.** To further characterize the signaling molecules involved in TREM-2–mediated DCs maturation, DCs were incubated with inhibitors of ERK (PD98049), NF-κB (TPCK), p38/SAPK (SB203580), and PTKs (PP2). Treated cells were stimulated with either F(ab')\textsubscript{2} anti–TREM-2 mAb, LPS, or immobilized IgG and subsequently analyzed for cell surface expression of maturation markers, such as CCR7, MHC class II, ICAM-1 CD83, CD40, and CD86. TREM-2–induced upregulation of CCR7, CD86, class II, and CD40, while cell surface expression of ICAM-1 and CD83 was not increased (Fig. 6, red bars). Remarkably, TREM-2–induced expression of CCR7, CD86, class II, and CD40 was completely blocked by a PTK inhibitor and partially blocked by an ERK inhibitor. This differential inhibitory capacity suggests that PTK may activate downstream signaling molecules other than ERK, which concur to TREM-2–mediated DC maturation. Incubation of DCs with NF-κB and p38/SAPK inhibitors had virtually no effect (Fig. 6, red bars).

LPS-induced maturation pathway was totally distinct from that mediated by TREM-2. LPS-induced upregulation of CCR7, MHC class II, ICAM-1 CD83, CD40, and CD86 (Fig. 6, green bars) (1). Incubation of DCs with NF-κB and p38/SAPK inhibitors prevented LPS-induced maturation, whereas ERK inhibitor had a modest effect, as described previously (Fig. 6, green bars) (72, 78). Finally, engagement of FcR by immobilized IgG induced a maturation pattern, which was similar to that induced by TREM-2, with the exception of an upregulation of ICAM-1 (Fig. 6, blue bars). Incubation of DCs with PTK and ERK inhibitors resulted in total and partial inhibition of FcR–induced maturation, respectively. These observations provide evidence that TREM-2 mediates DC maturation by PTK/ERK–dependent pathways. These pathways overlap with those initiated by FcRs, but are distinct from the NF-κB and p38/SAPK–dependent pathways triggered by LPS.

**Discussion**

We have shown that TREM-2 is an activating receptor expressed on monocyte-derived DCs, which activates PTK and ERK signaling through the association with DAP12, an ITAM–containing adaptor molecule (44, 45). TREM-2/DAP12–mediated signaling promotes survival of DCs...
and upregulation of CCR7, MHC class II, CD86, and CD40. Compared with the classical DC activation triggered by LPS, the TREM2/DAP12 pathway does not lead to upregulation of ICAM-1 and CD83 or secretion of IL-12, and is entirely independent of NF-κB and p38/SAPK signaling. TREM2/DAP12-induced DC maturation is more similar to that initiated by the FcRs, through the association FcRγ, another ITAM-containing adaptor molecule (42). Indeed, here we have shown that FcR-mediated maturation is dependent on PTK and ERK signaling.

This study is the first to show that a DAP12-mediated pathway can activate human DCs. What could be the physiological significance of this maturation pathway? TREM-2 or other DAP12-associated receptors could synergize with cell surface receptors, which activate DCs through NF-κB. This possibility is consistent with previous work on TREM-1, another DAP12-associated myeloid receptor (53), which is upregulated on neutrophils upon exposure to LPS and synergizes with LPS in promoting inflammatory responses to bacterial infections (79, 80). Thus, DAP12-associated DC receptors could amplify maturation signals transduced by other receptors, allowing for optimal antigen presentation. DAP12-mediated DCs activation could also be important in the normal homeostasis of DCs. TREM-2 induces upregulation of CCR7, which plays a pivotal role in directing DCs from the periphery to the T cell rich areas of draining lymph nodes (10–14). Thus, in the absence of pathogens, DAP12-associated receptors could regulate the homeostatic circulation of DCs from the periphery to the lymph nodes, allowing for renewal of lymph node DCs. In addition, TREM-2 induces upregulation of some T cell stimulatory molecules, such as MHC class II, CD40, and CD86. Thus, DAP12-mediated maturation of DCs may promote partial activation of T cells in the absence of exogenous antigens. This activation presumably is critical for the survival of T cells and the homeostasis of T cell populations (81).

We have demonstrated that crosslinking of TREM-2 promotes DC survival. This observation is consistent with previous demonstration that ERK signaling prevents apoptosis of LPS-stimulated DCs (71). In addition, we have evidence that TREM-1/DAP12 complex promotes survival of neutrophils and monocytes (unpublished data). Together, these observations suggest that DAP12-mediated pathways are critical for myeloid cell survival. Based on our data and previous studies in other systems, DAP12-mediated ERK activation is likely to induce phosphorylation of Bad or other Bcl-2 inhibitors (82–84). Once released from inhibition, Bcl-2 could translocate into the mitochondria and inhibit DC apoptosis (85–88).

The physiological functions of DAP12-mediated DC activation are consistent with the reported phenotypes of knock-in mice bearing a nonfunctional DAP12 and DAP12-deficient mice (57, 58). ITAM-deficient DAP12-knock-in mice showed an accumulation of DCs in mucocutaneous epithelia, associated with an impaired hapten-specific contact sensitivity (57). Our data suggest that this phenotype may be explained in part by a reduced ability of DCs to upregulate CCR7 expression and to respond to CCL19 and CCL21, affecting the migration of DCs to the T cell zone of draining lymph nodes. DAP12-deficient mice were resistant to EAE and resistance was associated with a strongly diminished production of IFN-γ by myelin-reactive CD4+ T cells (58). Our results suggest that this phenotype may be partly due to a reduced amplification of chemotactic and maturation signals by DAP12-associated receptors, resulting in an inadequate T cell priming in vivo.

Human TREM-2 is the first DAP12-associated receptor identified on DCs. TREM-2 is expressed on immature monocyte-derived DCs, but not on mature DCs or primary blood DCs. In addition, mouse TREM-2 transcripts were recently observed in cultured macrophage cell lines (54). Thus, more DAP12-associated receptors are likely to

---

**Figure 6.** Comparison of TREM-2-, LPS/TLR-, and FcR-mediated maturation pathways. Monocyte-derived DCs were stimulated with plastic-bound control F(ab′)2 (black bars), F(ab′)2 anti–TREM-2 (red bars), human IgG (blue bars), or LPS (green bars) in the presence of inhibitors for Erk (PD98059), p38/SAPK (SB203580), PTK (PP2), IκBα degradation (TPCK), or an equal volume of DMSO as a control. After 48 h, cell surface expression of CD86 (top left panel), MHC class II (middle left panel), CD40 (bottom left panel), CD83 (top right panel), ICAM-1 (middle right panel), or CCR7 (bottom right panel) was determined by flow cytometry. Data shown are representative of four independent experiments and display the mean and standard deviation of three independent samples.
be expressed on blood and tissues DCs. In addition, such receptors might be expressed not only in immature DCs, but also in mature DCs, regulating critical functions, such as IL-12 secretion. To fully understand the physiological functions of DAP12 in DCs, it will be important to identify all the DAP12-associated DC receptors, their level of expression in different maturation stages, and their ligands.

We thank Rachel Ettinger, Greg Klein, and Fraser McBlane for reviewing the manuscript, and Lena Angman for technical assistance.

The Basel Institute for Immunology was founded and is supported by Hoffmann-LaRoche Ltd., CH-4002 Basel.

Submitted: 3 July 2001
Accepted: 8 August 2001

References

1. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the control of immunity. Nature. 392:245–252.
2. Gallucci, S., M. Lolkema, and P. Matzinger. 1999. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 11:1249–1255.
3. Sauter, B., M.L. Albert, L. Francisco, M. Larsson, S. Somersan, and N. Bharadwaj. 2000. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191:423–434.
4. Dieu, M.C., B. Vanbervliet, A. Vicari, J.M. Bridon, E. Oldham, S. Ait-Yahia, F. Briere, A. Zlotnik, S. Lebecque, and C. Caux. 1998. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 188:373–386.
5. Sozzani, S., P. Allavena, G. D’Amico, W. Luini, G. Bianchi, M. Kataura, T. Imai, O. Yoshie, R. Bonecchi, and A. Mantovani. 1998. Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J. Immunol. 161:1083–1086.
6. Yanagihara, S., E. Komura, J. Nagafune, H. Watarai, and Y. Yamaguchi. 1998. EB11/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. J. Immunol. 161:3096–3102.
7. Sallusto, F., P. Schaerli, P. Loetscher, P. Schaniel, D. Lenig, C.R. Mackay, S. Qin, and A. Lanzavecchia. 1998. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur. J. Immunol. 28:2760–2769.
8. Cyster, J.G. 2000. Leukocyte migration: scent of the T zone. Curr. Biol. 10:R30–R33.
9. Zlotnik, A., and O. Yoshie. 2000. Chemokines: a new classification system and their role in immunity. Immunity. 12: 121–127.
10. Forster, R., A. Schubel, D. Breitfeld, E. Kremmer, I. Renner-Muller, E. Wolf, and M. Lipp. 1999. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell. 99:23–33.
11. Nakano, H., S. Morl, H. Yonekawa, H. Nariuchi, A. Matsuzawa, and T. Kakiuchi. 1998. A novel mutant gene involved in T-lymphocyte-specific homing into peripheral lymphoid organs on mouse chromosome 4. Blood. 91:2886–2895.
12. Saeki, H., A.M. Moore, M.J. Brown, and S.T. Hwang. 1999. Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J. Immunol. 162:2472–2475.
13. Gunn, M.D., S. Kyuwa, C. Tam, T. Kakiuchi, A. Matsuzawa, L.T. Williams, and H. Nakano. 1999. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J. Exp. Med. 189:451–460.
14. Ngo, V.N., H. Korner, M.D. Gunn, K.N. Schmidt, D.S. Rimmont, M.D. Cooper, J.L. Browning, J.D. Sedgwick, and J.G. Cyster. 1999. Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J. Exp. Med. 189:403–412.
15. Lanzavecchia, A. 1998. Immunology. Licence to kill. Nature. 393:413–414.
16. Armitage, R.J., C.R. Maliszewski, M.R. Alderson, K.H. Grabstein, M.K. Spriggs, and W.C. Fanslow. 1993. CD40L: a multi-functional ligand. Semina. Immunol. 5:401–412.
17. Anderson, D.M., E. Maraskovsky, W.L. Billingsley, W.C. Dougall, M.E. Tometsko, E.R. Roux, M.C. Teepe, R.F. DuBoise, D. Cosman, and L. Galibert. 1997. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 390:175–179.
18. Murata, K., N. Ishii, H. Takano, S. Miura, L.C. Ndhlovu, M. Nose, T. Noda, and K. Sugamura. 2000. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J. Exp. Med. 191:365–374.
19. Bachmann, M.F., B.R. Wong, R. Josien, R.M. Steinman, A. Oexnius, and Y. Choi. 1999. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J. Exp. Med. 189:1025–1031.
20. Josien, R., H.L. Li, E. Ingulli, S. Sarma, B.R. Wong, M. Vologodskaia, R.M. Steinman, and Y. Choi. 2000. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J. Exp. Med. 191:495–502.
21. Chen, A.I., A.J. McAdam, J.E. Buhlmann, S. Scott, M.L. Lusher, Jr., E.A. Greenfield, P.R. Baum, W.C. Fanslow, D.M. Calderhead, G.J. Freeman, and A.H. Sharpe. 1999. OX40 ligand has a critical costimulatory role in dendritic cell: T cell interactions. Immunity. 11:689–698.
22. Kong, Y.Y., H. Yoshida, I. Sarosi, H.L. Tan, E. Timms, C. Capparelli, S. Morony, A.J. Oliveira-dos-Santos, G. Van, A. Itie, et al. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 397:315–323.
23. Macatonia, S.E., N.A. Hosken, M. Litton, P. Vieira, C.S. Hsieh, J.A. Culpepper, M. Wysocka, G. Trinchieri, K.M. Murphy, and M. O’Garra. 1995. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J. Immunol. 154:5071–5079.
24. Cella, M., D. Scheidegger, K. Palmer-Lehmann, P. Lane, A. Lanzavecchia, and G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747–752.
25. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufer, E. Kampgen, N. Roman, and G. Schuler. 1996. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184:741–746.
26. Heufer, C., F. Koch, U. Stanzl, G. Topar, M. Wysocka, G.
27. Ohshima, Y., Y. Tanaka, H. Tozawa, Y. Takahashi, C. Maliszewski, and G. Delespesse. 1997. Expression and function of OX40 ligand on human dendritic cells. J. Immunol. 159: 3838–3848.

28. Aderem, A., and R.J. Ulevitch. 2000. Toll-like receptors in the induction of the innate immune response. Nature. 406: 782–787.

29. Medzhitov, R., and C. Janeway, Jr. 2000. Innate immunity. N. Engl. J. Med. 343:338–344.

30. Baldwin, A.S., Jr. 2001. Series introduction: the transcription factor NF-kappaB and human disease. J. Clin. Invest. 107: 3–6.

31. Ghosh, S., M.J. May, and E.B. Kopp. 1998. NF-kappaB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16:225–260.

32. Baeuerle, P.A. 1998. IkappaB-NF-kappaB structures: at the interface of inflammation control. Rev Immunol. 14:371–380.

33. Karin, M., and Y. Ben-Neriah. 2000. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 18:621–663.

34. Kawamata, S., T. Hori, A. Imura, A. Takaori-Kondo, and T. Uchiyama. 1998. Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2– and TRAF5-mediated NF-kappaB activation. J. Biol. Chem. 273:5808–5814.

35. Regnault, A., D. Lankar, V. Lacabanne, A. Rodriguez, C. Thery, M. Rescigno, T. Saito, S. Verbeek, C. Bonnerot, P. Ricciardi-Castagnoli, and S. Amigorena. 1999. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189:371–380.

36. Ravetch, J.V., and S. Bolland. 2001. IgG fc receptors. Annu Rev Immunol. 19:275–290.

37. Arch, R.H., and C.B. Thompson. 1998. 4–1BB and OX40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. Mol. Cell. Biol. 18: 558–565.

38. Bouchon, A., J. Dietrich, and M. Colonna. 2000. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J. Immunol. 164:9–12.

39. Fairfield, F., A. Banchereau, A. Chaffai, J. Dietrich, and M. Colonna. 1998. Immunoreceptor DAP12-associated lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells. Proc. Natl. Acad. Sci. USA. 96:9792–9796.

40. Dietrich, J., M. Cella, M. Seifert, H.J. Buhring, and M. Colonna. 2000. Cutting edge: signal-regulatory protein beta 1 is a DAP12-associated activating receptor expressed in myeloid cells. J. Immunol. 164:9–12.

41. Moretta, A., and E. Vivier. 1997. Human killer cell activatory receptors for MHC class I molecules are included in a multimeric complex expressed by natural killer cells. J. Immunol. 158:5083–5086.

42. Lanier, L.L., V. Blander, J. Wu, C. Leong, and J.H. Phillips. 1998. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature. 391: 703–707.

43. Lanier, L.L., B. Corliss, J. Wu, and J.H. Phillips. 1998. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity. 6:693–701.

44. Tomasello, E., L. Olcese, F. Vely, C. Geourgeon, M. Bleyer, A. Moqrich, D. Gautheret, M. Djabali, M.G. Mattei, and E. Vivier. 1998. Gene structure, expression pattern, and biological activity of mouse killer cell activating receptor-associated protein (KARAP)/DAP-12. J. Biol. Chem. 273:34115–34119.

45. Smith, K.M., J. Wu, A.B. Bakker, J.H. Phillips, and L.L. Lanier. 1998. Ly-49D and Ly-49H associate with mouse DAP12 and form activating receptors. J. Immunol. 161:7–10.

46. Cantoni, C., C. Bottino, M. Vitale, A. Pessino, R. Augugliaro, A. Malaspina, S. Pololim, L. Moretta, A. Moretta, and R. Biassoni. 1999. Nkp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J. Exp. Med. 189:787–796.

47. Mason, L.H., J. Willeit-Brown, A.T. Mason, D. McVicar, and J.R. Ortaldo. 2000. Interaction of Ly-49D+ NK cells with H-2Dd target cells leads to Dap-12 phosphorylation and IFN-gamma secretion. J. Immunol. 164:603–611.

48. Bouchon, A., J. Dietrich, and M. Colonna. 2000. Cutting edge: signal-regulatory protein beta 1 is a DAP12-associated activating receptor expressed in myeloid cells. J. Immunol. 164:9–12.

49. Thomas, E., V. Blander, A. Goddard, J. Bub, B.K. Geha, M.C. Nakamura, P. Linne-meyer, W.E. Seaman, S.K. Anderson. 1998. DAP12-mediated signal transduction in natural killer cells. PLoS Pathog. 1:4.491–4995.

50. Daws, M.R., L.L. Lanier, W.E. Seaman, and J.C. Ryan. 2001. Cloning and characterization of a novel mouse myeloid DAP12-associated receptor family. J. Immunol. 167:783–791.

51. McVicar, D.W., L.S. Taylor, P. Gosselin, J. Willeit-Brown, A.I. Michael, R.L. Gehaeh, M.C. Nakamura, P. Linne-meyer, W.E. Seaman, S.K. Anderson. 1998. DAP12-mediated signal transduction in natural killer cells. A dominant role for the Syk protein-tyrosine kinase. J. Biol. Chem. 273: 32934–32942.

52. Campbell, K.S., M. Cellia, M. Carretero, M. Lopez-Botet, and M. Colonna. 1998. Signaling through human killer cell activating receptors triggers tyrosine phosphorylation of an associated protein complex. Eur. J. Immunol. 28:599–609.

53. Bouchon, A., J. Dietrich, and M. Colonna. 2000. Combined natural killer cell and dendritic cell func-
tional deficiency in KARAP/DAP12 loss-of-function mutant mice. *Immunity.* 13:355–364.
58. Bakker, A.B., R.M. Hock, A. Cerverenka, B. Blom, L. Lucian, T. McNeil, R. Murray, L.H. Phillips, J.D. Sedgwick, and L.L. Lanier. 2000. DAP12-deficient mice fail to develop autoimmune disease due to impaired antigen priming. *Immunity.* 13:345–353.
59. Khartonovnenk, A., Z. Chen, I. Sures, H. Wang, J. Schilling, and A. Ullrich. 1997. A family of proteins that inhibit signaling through tyrosine kinase receptors. *Nature.* 386:181–186.
60. Seiffert, M., P. Brossart, C. Cant, M. Celli, M. Colonna, W. Brugger, L. Kanz, A. Ullrich, and H.J. Buhring. 2001. Signal-regulatory protein alpha (SIRPα) but not SIRPβ is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34+CD38- hematopoietic cells. *Blood.* 97:2741–2749.
61. Traunecker, A., F. Oliveri, and K. Karjalainen. 1991. Myeloma based expression system for production of large mammalian proteins. *Trends Biotechnol.* 9:109–113.
62. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. *J. Exp. Med.* 179:1109–1118.
63. Bender, A., M. Sapp, G. Schuler, R.M. Steinman, and N. Nicoletti, I., G. Migliorati, M.C. Pagliacci, F. Grignani, and M.S. Krangel. 1994. Regulation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. *J. Exp. Med.* 179:1109–1118.
64. Bender, A., M. Sapp, G. Schuler, R.M. Steinman, and N. Bhardwaj. 1996. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. *J. Immunol. Methods.* 196:121–135.
65. Cella, M., A. Eugering, V. Pinet, J. Peters, and A. Lanzavecchia. 1997. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. *Nature.* 388:782–787.
66. Nicoletti, I., G. Migliorati, M.C. Pagliacci, F. Grignani, and C. Riccardi. 1991. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. *J. Immunol. Methods* 139:271–279.
67. Schreiber, E., P. Matthias, M.M. Muller, and W. Schaffner. 1989. Rapid detection of octamer binding proteins with ‘mini-extracts’, prepared from a small number of cells. *Nucleic Acids Res.* 17:6419.
68. Hernandez-Munain, C., and M.S. Krangel. 1994. Regulation of the T-cell receptor delta enhancer by functional cooperation between c-Myb and core-binding factors. *Mol. Cell. Biol.* 14:473–483.
69. Wu, J., Y. Song, A.B. Bakker, S. Bauer, T. Spies, L.L. Lanier, and J.H. Phillips. 1999. An activating immunoreceptor complex formed by NKG2D and DAP10. *Science.* 285:730–732.
70. Nakajima, H., J. Samaridis, L. Angman, and M. Colonna. 1999. Human myeloid cells express an activating ILT receptor (ILT1) that associates with Fc receptor gamma-chain. *J. Immunol.* 162:5–8.
71. Makrigiannis, A.P., P. Gosselin, L.H. Mason, L.S. Taylor, D.W. McVicar, J.R. Ortoldo, and S.K. Anderson. 1999. Cloning and characterization of a novel activating Ly49 closely related to Ly49A. *J. Immunol.* 163:4931–4938.
72. Ardesha, K.M., A.R. Pizzey, S. Devereux, and A. Khwaja. 2000. The PI3 kinase, p38 SAP kinase, and NF-κappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. *Blood.* 96:1039–1046.
73. Robbiani, D.F., R.A. Finch, D. Jager, W.A. Muller, A.C. Sartorelli, and G.J. Randolph. 2000. The leukotriene C4(C) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. *Cell.* 103:757–768.
74. Dori, T.S., T. Takahashi, O. Taguchi, T. Azuma, and Y. Obata. 1997. NF-κappa B RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses. *J. Exp. Med.* 185:953–961.
75. Kontgen, F., R.J. Grumont, A. Strasser, D. Metcalf, R. Li, D. Tarlinton, and S. Gerondakis. 1995. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. *Genes Dev.* 9:1965–1977.
76. Sha, W.C., H.C. Liou, E.I. Tuomanen, and D. Baltimore. 1995. Targeted disruption of the p50 subunit of NF-κappa B leads to multifocal defects in immune responses. *Cell.* 80:321–330.
77. Lin, Y.C., K. Brown, and U. Siebenlist. 1995. Activation of NF-κappa B requires proteolysis of the inhibitor I kappa B-alpha: signal-induced phosphorylation of I kappa B-alpha alone does not release active NF-κappa B. *Proc. Natl. Acad. Sci. USA.* 92:552–556.
78. Arrighi, J.F., M. Rebsamen, F. Rousset, V. Kindler, and C. Hainer. 2001. A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. *J. Immunol.* 166:3837–3845.
79. Bouchon, A., F. Facchetti, M.A. Weigand, and M. Colonna. 2001. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. *Nature.* 410:1103–1107.
80. Nathan, C., and A. Ding. 2001. TREM-1: a new regulator of innate immunity in sepsis syndrome. *Nat. Med.* 7:530–532.
81. Tanchot, C., F.A. Lemonnier, B. Perarnau, A.A. Freitas, and R. Kocha. 1997. Differential requirements for survival and proliferation of CD8 naive or memory T cells. *Science.* 276:2057–2062.
82. Scheid, M.P., and V. Duronio. 1998. Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation. *Proc. Natl. Acad. Sci. USA.* 95:7439–7444.
83. Scheid, M.P., K.M. Schubert, and V. Duronio. 1999. Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase. *J. Biol. Chem.* 274:31108–31113.
84. Klein, J.B., M.J. Rane, J.A. Scherer, P.Y. Coxon, R. Kettritz, J.M. Mathiesen, A. Buridi, and K.R. McLeish. 2000. Granulocyte-macrophage colony-stimulating factor delays neutrophil constitutive apoptosis through phosphoinositide 3-kinase and extracellular signal-regulated kinase pathways. *J. Immunol.* 164:4286–4291.
85. Adams, J.M., and S. Cory. 1998. The Bcl-2 protein family: arbiters of cell survival. *Science.* 288:1322–1326.
86. Grenn, D.R. 2000. Apoptotic pathways: paper wraps stone blunts scissors. *Cell.* 102:1–4.
87. Huang, D.C., and A. Strasser. 2000. BH3-only proteins—essential initiators of apoptotic cell death. *Cell.* 103:839–842.
88. Gross, A., J.M. McDonnell, and S.J. Korsmeyer. 1999. Bcl-2 family members and the mitochondria in apoptosis. *Genes Dev.* 13:1899–1911.